Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC).

被引：0
|
作者：
Nabhan, Chadi
Villines, Dana
Valdez, Tina V.
Tolzien, Kathy
Lestingi, Timothy M.
Bitran, Jacob D.
Susan, Christner M.
Egorin, Merrill J.
Beumer, Jan H.
机构：
[1] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[2] Oncol Specialists SC, Park Ridge, IL USA
[3] Advocate Illinois Masonic Hosp, Chicago, IL USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    Nabhan, C.
    Villines, D.
    Valdez, T. V.
    Tolzien, K.
    Lestingi, T. M.
    Bitran, J. D.
    Christner, S. M.
    Egorin, M. J.
    Beumer, J. H.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 592 - 597
  • [2] Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    C Nabhan
    D Villines
    T V Valdez
    K Tolzien
    T M Lestingi
    J D Bitran
    S M Christner
    M J Egorin
    J H Beumer
    British Journal of Cancer, 2012, 107 : 592 - 597
  • [3] Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Danila, D. C.
    Montgomery, B.
    Shelkey, J.
    Hirmand, M.
    Hung, D.
    Sawyers, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
    Stein, M. N.
    Chen, Y.
    Hudes, G. R.
    Carducci, M. A.
    Tan, W.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.
    Nabhan, Chadi
    Cygan, Peter Hubert
    Meyer, Andrew
    Tolzien, Kathy
    Galvez, Angel G.
    Lestingi, Timothy M.
    Bitran, Jacob D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [6] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [7] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [8] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [9] Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC)
    Nabhan, C.
    Tolzien, K.
    Lestingi, T. M.
    Galvez, A.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345